Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | DOI: 10.5507/bp.2024.040

FOXP3, IL-35, and PD-L1 in intra- and peritumoral lymphocytic infiltrate of cutaneous melanomas as an important part of antitumor immunity

Vladimir Zidlik1, 2, Pavel Hurnik1, 2, Yvetta Vantuchova3, Simona Michalcova3, Jozef Skarda1, 2, 4, Tereza Hulinova1, 2, Dana Purova5, Jiri Ehrmann1, 4
1 Institute of Pathology and Molecular Genetics, Faculty Hospital Ostrava, Ostrava, Czech Republic
2 Institute of Clinical and Molecular Pathology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
3 Department of Dermatology, Faculty Hospital Ostrava, Ostrava, Czech Republic
4 Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
5 Social Health Institute, Palacky University Olomouc, Olomouc, Czech Republic

Background: The tumor microenvironment is a significant mediator enabling tumor growth and progression. Tumor-infiltrating lymphocytes (TILs) are an important component of this but tumor cells develop mechanisms by which they can escape the action of the immune system. Immunosuppressive mechanisms cooperate with each other and involve cells of the immune system, the tumor microenvironment itself, chemokines and cytokines. In this study, we examined the FOXP3+, IL-35+, and PD-L1+ lymphocytes in tumor tissues as they are contributing to immunosuppression in some tumors, including melanoma. Such cells are also associated with tumor progression, early metastasis, and prognosis.

Methods and Results: In this study, 95 cutaneous melanomas and 25 melanocytic nevi as a control group were examined by immunohistochemistry for FOXP3+, IL-35+, and PD-L1+ lymphocytes. Melanomas were divided into four groups according to the TNM classification: pT1 (35), pT2 (21), pT3 (21), and pT4 (18). PD-L1+ lymphocytes were enriched in pT3- and pT4-stage melanomas, especially in the periphery of the lesions (P<0.001). The number of FOXP3+ lymphocytes was positively correlated with the stage of the disease, especially in the center of the tumors (P<0.001). Likewise, IL-35+ lymphocytes (P<0.001) were enriched with the stage of the tumor.

Conclusion: This article demonstrates that the immunosuppressive environment develops in proportion to the stage of the melanoma. The most significant changes are found at the tumor periphery, confirming the heterogeneity of the tumor stroma which is more pronounced in more advanced tumors and which may contribute to the greater aggressiveness in these peripheral zones.

Keywords: cutaneous melanoma, tumor microenvironment, tumor-infiltrating lymphocytes, immunosuppression, immune checkpoints

Received: September 11, 2024; Revised: November 4, 2024; Accepted: December 17, 2024; Prepublished online: January 22, 2025 

Download citation

References

  1. Brychtova S, Bezdekova M, Hirnak J, Sedlakova E, Tichy M, Brychta T. Stromal Microenvironment Alterations in Malignant Melanoma. (2011) Available from: https://www.intechopen.com/chapters/19104 [accessed Sep 12, 2011] Go to original source...
  2. Chlopik A, Selim AM, Peng Y, Wu ChL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP. Prognostic role of tumoral PDL1 expression and peritumoral FoxP3+ lymphocytes in vulvar melanomas. Hum Pathol 2018;73:176-83. Go to original source... Go to PubMed...
  3. Gupta PY. Molecular pathways: Interleukin-35 in autoimmunity and cancer. Clin Cancer Res 2016;22(20):4973-8. Go to original source... Go to PubMed...
  4. Teymouri M, Pirro M, Fallarino F, Gargano M, Sahebkar A. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases. Int J Cancer 2018;143(9):2105-15. Go to original source... Go to PubMed...
  5. Garutti M, Bruno R, Polesel J, Pizzichetta MA, Puglisi F. Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis. Heliyon 2024;10(12):e32433. Go to original source... Go to PubMed...
  6. Lucas S, Baren van N, Smet de C, Coulie PG. Demethylation of the FOXP3 gene in human melanoma cells preclude the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples. Int J Cancer 2012;130(8):1960-6. Go to original source... Go to PubMed...
  7. Fontenot DJ, Gavin AM, Rudevsky YA. FOXP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4(4):330-6. Go to original source... Go to PubMed...
  8. Wing BJ, Tanaka A, Sakaguchi S. Human FOXP3+ Regulatory T cells heterogeneity and Function in Autoimmunity cancer. Immunity 2019;50(2):302-16. Go to original source... Go to PubMed...
  9. Huang L, Guo Y, Liu S, Wang H, Zhu J, Ou L, Xu X. Targeting regulatory T cells for immunotherapy in melanoma. Mol Biomed 2021;2(1):11. Go to original source... Go to PubMed...
  10. Cioplea M, Nichita L, Georgescu D, Sticlaru L, Cioroianu A, Nedelcu R, Turcu G, Rauta A, Mogodici C, Zurac S, Popp C. FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation. J Immunol Res 2020;2020:5416843. doi: 10.1155/2020/5416843 Go to original source... Go to PubMed...
  11. Kourko O, Seaver K, Odoardi N, Basta S, Gee K. IL-27, IL-30 and IL-35: A Cytokine Triumvirate in Cancer. Front Oncol 2019;9:969. Go to original source... Go to PubMed...
  12. Xue W, Yan D, Kan Q. Interleukin-35 as an Emerging Player in Tumor Microenvironment. J Cancer 2019;10(9):2074-82. Go to original source... Go to PubMed...
  13. Turnis EM, Sawant VD, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, Beres AJ, Vogel P, Workman CJ, Vignali DAA. Interleukin-35 limits anti tumor immunity. Immunity 2016;44(2):316-29. Go to original source... Go to PubMed...
  14. Wang Z, Liu J, Liu Z, Shen R, Zhang G, Xu J, Basu S, Feng Y, Bai XF. Tumor-Derived Il-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis. J Immunol 2013;190(5):2415-23. Go to original source... Go to PubMed...
  15. Chauvin JM, Zarour MB. TIGIT in cancer immunotherapy, J Immunother Cancer 2020;8(2):e000957. Go to original source... Go to PubMed...
  16. De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). Curr Oncol Rep 2021;23(11):126. Go to original source... Go to PubMed...
  17. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 2016;44(5):989-1004. Go to original source... Go to PubMed...
  18. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin in Immunol 2015;33:23-35. Go to original source... Go to PubMed...
  19. Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer 2020;19(1):19. Go to original source... Go to PubMed...
  20. Ye L, Leslie C, Jacques A, Ardakani NM, Amanuel B, Millward M. Programmed death ligand-1 expression in non-small cell lng cancer in a Western Australian population and correalation with clinicopathlogic features. Mod Pathol 2019;32(4):524-31. Go to original source... Go to PubMed...
  21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman WH, Pages F. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4. Go to original source... Go to PubMed...
  22. Albini A, Bruno A, Gallo C, Pajardi G, Noonan DM, Dallaglio K. Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res 2015;56(5):414-25. Go to original source... Go to PubMed...
  23. Tan B, Anaka M, Deb S, Freyer S, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, Chen W, Mariadason JM. FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget 2014;5(1):264-76. Go to original source... Go to PubMed...
  24. Lal A, Chan L, DeVries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat 2013;139(2):381-90. Go to original source... Go to PubMed...
  25. Kim M, Grimmig T, Grimm M, Lazariotu M, Meier E, Rosenwald A, Tsaur I, Blaheta R, Heemann U, Germer C-T, Waaga-Gasser AM, Gasser M. Expression of FOXP3 in Colorectal Cancer but Not in Treg Cells Correlates with Disease Progression in Patients with Colorectal Cancer. PLoS One 2013;8(1):e53630. Go to original source... Go to PubMed...
  26. Wang J, Zhao X, Wan YY. Intricacies of TGF-β signaling in Treg and Th17 cell biology. Cell Mol Immunol 2023;20(9):1002-22. Go to original source... Go to PubMed...
  27. Apostolou I, Verginis P, Kretschmer K, Polansky J, Hühn J, Boehmer H. Peripherally Induced Treg: Mode, Stability, and Role in Specific Tolerance. J Clin Immunol 2008;28(6):619-24. Go to original source... Go to PubMed...
  28. Wei X, Zhang J, Gu Q, Huang M, Zhang W, Guo J, Zhou X. Reciprocal Expression of IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are Required for Maintenance of Immune Tolerance. Cell Rep 2017;21(7):1853-69. Go to original source... Go to PubMed...
  29. Langhans B, Nischalke HD, Krämer B, Dold L, Lutz P, Mohr R, Vogt A, Toma M, Eis-Hubinger AM, Nattermann J, Strassburg CP, Gonzales-Carmona MA, Spengler U. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother 2019;68(12):2055-66. Go to original source... Go to PubMed...
  30. Yazdani Z, Rafei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL-35, a double-edge sword in cancer. J Cell Biochem 2020;121(3):2064-76. Go to original source... Go to PubMed...
  31. Ye C, Yano H, Workman CJ, Vignali DAA. Interleukin-35: Structure, Function and Its Impact on Immune-Related Disease. J Interferon Cytokine Res 2021;41(11):391-406. Go to original source... Go to PubMed...
  32. Zhang J, Mao T, Wang S, Wang D, Niu Z, Sun Z, Zhang J. Interleukin-35 expression is associated with colon cancer progression. Oncotarget 2017;8(42):71563-73. Go to original source... Go to PubMed...
  33. Ma Y, Chen L, Xie G, Zhou Y, Yue C, Yuan X, Zheng Y, Wang W, Deng L, Shen L. Elevated level of Interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3. Oncotarget 2016;7(45):73003-15. Go to original source... Go to PubMed...
  34. Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL-10+ and IL-35+ Treg dells cooperatively promotes tumor T cell exhaustion. Nat Immunol 2019;20(6):724-35. Go to original source... Go to PubMed...
  35. Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F. PD-L1 Expression Is Associated with Tumor FOXP3+ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. J Cancer 2016;7(7): 784-93. Go to original source... Go to PubMed...
  36. Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Rodig S, Mihm jr. M, Neto CF, Duncan LM, Kalil J. Nodular primary cutaneous melanoma is associated with PD-L1 expression. Eur J Dermatol 2020;30(4):352-7. Go to original source... Go to PubMed...
  37. Liu K, Huang A, Nie J, Tan J, Xing S, Qu Y, Jiang K. IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment. Front Immunol 2021;12:683332. Go to original source... Go to PubMed...
  38. Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caraco C, Botti G, Fox BA, Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. Oncoimmunology 2018;7(12):e1405206. Go to original source... Go to PubMed...
  39. Zhu Y, Li M, Mu D, Kong L, Zhang J, Zhao F, Li Z, Liu X, Bo C, Yu J. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget 2016;7(44):71455-65. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.